Abstract
Borderline personality disorder (BPD) is a common mental disorder characterized by a pervasive pattern of emotional Borderline personality disorder (BPD) is a common mental disorder characterized by a pervasive pattern of emotional lability, impulsivity, interpersonal difficulties, identity disturbances, and disturbed cognition. Traditional pharmacotherapies are effective in treating some of these core symptoms but have only modest effects on the domain of interpersonal dysfunction of BPD. Thus there is a need to develop new, neurobiologically informed pharmacological treatments for BPD. This review focuses on the potential use of intranasal oxytocin (OXT), which has key roles in the regulation of complex social cognition and behaviors, to target symptoms of interpersonal dysfunction in BPD. Surprisingly, despite promising data on the prosocial effects of OXT, only 5 trials in BPD have been published to date. These trials show mixed results with on one hand, a decrease of emotional responses to stress and on the other hand, some "paradoxical" reactions with worsened interpersonal anxiety and decreased cooperative behavior. These mixed results are interpreted according to different theoretical models and also in light of some methodological limitations. Further studies are needed to understand the effect of OXT in patients with BPD and ongoing clinical trials will provide some answers to remaining questions on the use of OXT in BPD. Recommendations for future studies are also proposed in this review.
Keywords: Borderline personality disorder, oxytocin, off-label.
Current Pharmaceutical Design
Title:Borderline Personality Disorder and Oxytocin: Review of Clinical Trials and Future Directions
Volume: 21 Issue: 23
Author(s): Ali Amad, Pierre Thomas and M. Mercedes Perez-Rodriguez
Affiliation:
Keywords: Borderline personality disorder, oxytocin, off-label.
Abstract: Borderline personality disorder (BPD) is a common mental disorder characterized by a pervasive pattern of emotional Borderline personality disorder (BPD) is a common mental disorder characterized by a pervasive pattern of emotional lability, impulsivity, interpersonal difficulties, identity disturbances, and disturbed cognition. Traditional pharmacotherapies are effective in treating some of these core symptoms but have only modest effects on the domain of interpersonal dysfunction of BPD. Thus there is a need to develop new, neurobiologically informed pharmacological treatments for BPD. This review focuses on the potential use of intranasal oxytocin (OXT), which has key roles in the regulation of complex social cognition and behaviors, to target symptoms of interpersonal dysfunction in BPD. Surprisingly, despite promising data on the prosocial effects of OXT, only 5 trials in BPD have been published to date. These trials show mixed results with on one hand, a decrease of emotional responses to stress and on the other hand, some "paradoxical" reactions with worsened interpersonal anxiety and decreased cooperative behavior. These mixed results are interpreted according to different theoretical models and also in light of some methodological limitations. Further studies are needed to understand the effect of OXT in patients with BPD and ongoing clinical trials will provide some answers to remaining questions on the use of OXT in BPD. Recommendations for future studies are also proposed in this review.
Export Options
About this article
Cite this article as:
Amad Ali, Thomas Pierre and Perez-Rodriguez Mercedes M., Borderline Personality Disorder and Oxytocin: Review of Clinical Trials and Future Directions, Current Pharmaceutical Design 2015; 21 (23) . https://dx.doi.org/10.2174/1381612821666150619093019
DOI https://dx.doi.org/10.2174/1381612821666150619093019 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diversity Oriented p-TSA Catalyzed Efficient and Environmentally Benign Synthetic Protocol for the Synthesis of Structurally Diverse Heteroannulated Benzothiazolopyrimidines
Current Organocatalysis Synthesis, Biological and Computational Evaluation of Novel Oxindole Derivatives as Inhibitors of Src Family Kinases
Letters in Drug Design & Discovery Obstructive Sleep Apnea Syndrome: An Emerging Risk Factor for Dementia
CNS & Neurological Disorders - Drug Targets Proteomic-Based Biomarker Discovery with Emphasis on Cerebrospinal Fluid and Multiple Sclerosis
Current Pharmaceutical Biotechnology Highlighting the Role of Cognitive and Brain Reserve in the Substance use Disorder Field
Current Neuropharmacology Dietary Approaches and Alternative Therapies for Polycystic Ovary Syndrome
Current Nutrition & Food Science Autologus Stem Cell Transplatation as a Care Option in Elderly Patients. A Review
Anti-Cancer Agents in Medicinal Chemistry Relapsing Remitting Multiple Sclerosis and its Relationship with the Immune System and Oxidative Stress
Current Immunology Reviews (Discontinued) Adverse Drug Reaction Labelling for Atomoxetine, Methylphenidate and Modafinil: Comparison of Product Information for Oral Formulations in Australia, Denmark and the United States
Current Drug Safety Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Nuclear Factor κB and Adenosine Receptors: Biochemical and Behavioral Profiling
Current Neuropharmacology GRK2 at the Control Shaft of Cellular Metabolism
Current Pharmaceutical Design Cyclin D1 Gene Silencing by siRNA in Ex Vivo Human Tissue Cultures
Current Drug Delivery Medicinal Plants in Neurodegenerative Diseases: Perspective of Traditional Persian Medicine
Current Drug Metabolism Recombinant Human Growth Hormone in Abstinent Androgenic-Anabolic Steroid Use: Psychological, Endocrine and Trophic Factor Effects
Current Neurovascular Research Monoamine Involvement in the Antidepressant-Like Effect of β-Caryophyllene
CNS & Neurological Disorders - Drug Targets Cognitive - Behavioral Therapy in Central Sensitivity Syndromes
Current Rheumatology Reviews 5-HT<sub>3</sub> Receptor Antagonism: A Potential Therapeutic Approach for the Treatment of Depression and other Disorders
Current Neuropharmacology The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Structure-Bioactivity Relationship Study of Xanthene Derivatives: A Brief Review
Current Organic Synthesis